Drug Trial Radar · NCT03548935
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Last checked: Nov 20, 2026Latest source record: Nov 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,961
Actual
Start
Jun 4, 2018
Primary completion
Mar 30, 2020
Study completion Mar 5, 2021
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jun 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants taking "dummy" medicine. In addition to taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what you can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which treatment participants get, is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study has two phases: A main phase and an extension phase.The main phase will last for about 1.5 years. Participants will have 15 clinic visits and 10 phone calls with the study doctor. Extension phase: Approximately 300 participants will continue in the extension phase in the following countries only: Canada, Germany, the UK and selected sites in the US and Japan. These participants will be in the study for about 2.5 years.They will not receive treatment, but will attend another 5 follow-up visits with the study doctor.
Conditions
- Metabolism and Nutrition Disorder
- Overweight or Obesity
Interventions
SemaglutideDrug
Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks. Dose escalation of semaglutide will take place as follows: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 68.
Placebo (semaglutide)Drug
Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Body Weight (%)Time frame: Baseline (week 0) to week 68
- Participants Who Achieve 5 or More Percent Body Weight Reduction (Yes/no)Time frame: After week 68
Locations
128 sites in 17 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Anniston, Alabama
Novo Nordisk Investigational Site
Anaheim, California
Novo Nordisk Investigational Site
Lomita, California
Novo Nordisk Investigational Site
Spring Valley, California
Novo Nordisk Investigational Site
Aurora, Colorado
Novo Nordisk Investigational Site
Waterbury, Connecticut
Novo Nordisk Investigational Site
Chiefland, Florida
Novo Nordisk Investigational Site
Crystal River, Florida
Novo Nordisk Investigational Site
Jacksonville, Florida
Novo Nordisk Investigational Site
Jacksonville, Florida
Novo Nordisk Investigational Site
Ocala, Florida
Novo Nordisk Investigational Site
Panama City, Florida
Novo Nordisk Investigational Site
Plantation, Florida
Novo Nordisk Investigational Site
Ponte Vedra, Florida
Novo Nordisk Investigational Site
Roswell, Georgia
Novo Nordisk Investigational Site
Chicago, Illinois
Novo Nordisk Investigational Site
Chicago, Illinois
Novo Nordisk Investigational Site
Indianapolis, Indiana
Novo Nordisk Investigational Site
Topeka, Kansas
Novo Nordisk Investigational Site
Louisville, Kentucky
Novo Nordisk Investigational Site
Buckley, Michigan
Novo Nordisk Investigational Site
City of Saint Peters, Missouri
Novo Nordisk Investigational Site
Butte, Montana
Novo Nordisk Investigational Site
Omaha, Nebraska
Novo Nordisk Investigational Site
Rochester, New York
Novo Nordisk Investigational Site
Salisbury, North Carolina
Novo Nordisk Investigational Site
Wilmington, North Carolina
Novo Nordisk Investigational Site
West Reading, Pennsylvania
Novo Nordisk Investigational Site
Charleston, South Carolina
Novo Nordisk Investigational Site
Simpsonville, South Carolina
Novo Nordisk Investigational Site
Nashville, Tennessee
Novo Nordisk Investigational Site
Austin, Texas
Novo Nordisk Investigational Site
Dallas, Texas
Novo Nordisk Investigational Site
Dallas, Texas
Novo Nordisk Investigational Site
Dallas, Texas
Novo Nordisk Investigational Site
Round Rock, Texas
Novo Nordisk Investigational Site
Bountiful, Utah
Novo Nordisk Investigational Site
Richmond, Virginia
Novo Nordisk Investigational Site
Renton, Washington
Novo Nordisk Investigational Site
CABA, Argentina
Showing 40 of 128 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.